ClinicalTrials.gg
CompletedNCT06679153Updated Jan 27, 2025

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

A Phase 2 interventional study of VVN461 Ophthalmic Solution 1.0% and VVN461 Ophthalmic Solution 0.5% in Anterior Uveitis, sponsored by VivaVision Biotech, Inc. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by VivaVision Biotech, Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Nov 2023, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a multicenter, double-masked, randomized, active-controlled, parallel-comparison study conducted at sites in the China in subjects with Noninfectious Anterior Uveitis

Read the detailed description

In this study, subjects who meet the inclusion/exclusion criteria will be randomized to receive one of the three treatments prednisolone acetate during the Screening/Baseline Visit (Day-2 to Day 1). Starting from Visit 1 (Day 1), subjects will be administered one drop of the investigational product in the study eye in following dose regimens: 6 times per day (Q2h, 2 hours apart) for 7 days; 4 times per day (QID) for 7 days;2 times per day (BID) for 7 days;once a day (QD) for 7 days. Subjects will return to clinic for study assessments on Day 3 (Visit 2), Day 7 (Visit 3), Day 14 (Visit 4), Day 21 (Visit 5) and Day 28 (Visit 6, end of study) or early withdrawal/termination visit.

02

Conditions studied

  • Anterior Uveitis

Browse trials for

03

In context

Uveitis, Anterior

56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.

This study's enrollment of 89 is above the median of 50 across 45 interventional studies indexed under Uveitis, Anterior.

Browse Uveitis, Anterior studies →

Lead sponsor

VivaVision Biotech, Inc is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-70 years at the time providing signed
  • At least 1 eye diagnosed with noninfectious anterior uveitis at the time of screening
  • Willing and able to comply with study requirements and visit schedule

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of intermediate uveitis, posterior uveitis or panuveitis in either eye at the time of screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    VVN461, 1.0%

    VVN461 Ophthalmic Solution, 1.0%

    Drug: VVN461 Ophthalmic Solution 1.0%

  • Experimental
    VVN461, 0.5%

    VVN461 Ophthalmic Solution, 0.5%

    Drug: VVN461 Ophthalmic Solution 0.5%

  • Placebo comparator
    Prednisolone acetate, 1%

    Prednisolone acetate Ophthalmic Solution, 1%

    Drug: Prednisolone acetate

Interventions

06

What researchers measure

Primary outcomes

  1. ACC score of ≥2 grade from baseline at Day 14

    Proportion of subjects with improvement in ACC score of ≥2 grade from baseline at Day 14

    Time frame: Day 14

Secondary outcomes

  1. ACC score of 0

    Proportion of subjects with an ACC score of 0 at any visit

    Time frame: Baseline to Day 28

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2024, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 7, 2024
StartActual
Nov 27, 2023
Primary completionActual
Dec 29, 2024
CompletionActual
Dec 29, 2024
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06679153
Lead sponsor
VivaVision Biotech, Inc
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Nov 27, 2023
Primary completion
Dec 29, 2024
Completion
Dec 29, 2024
Last update
Jan 27, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VVN461

Start the discussion